Progenra, Inc. is pursuing novel approaches to therapeutic intervention of the ubiquitin proteasome system based upon proprietary technology encompassed under its UbiPro™ Drug Discovery Platform. Key discoveries and unsurpassed know-how are creating new opportunities for ameliorating diseases in a number of therapeutic areas. Progenra’s multi-faceted approach addresses the known heterogeneity of the sites at which enzymes of the ubiquitin proteasome system interact with their substrates under physiological conditions. This approach has allowed Progenra's scientists to make breakthroughs in developing drug candidates for evaluation and progression in the clinic.